Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 05, 2019 06:00 ET | Source: Mesoblast Limited

Mesoblast to Present at Upcoming Global Life Sciences Conference in London

NEW YORK and MELBOURNE, Australia, April 05, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced an...
March 26, 2019 11:00 ET | Source: Mesoblast Limited

Memorandum of Understanding for Confirmatory Trial to Support Marketing Approval of Revascor for Reduction of Gastrointestinal Bleeding in LVAD Patients

NEW YORK and MELBOURNE, Australia, March 26, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced that...
March 25, 2019 06:00 ET | Source: Mesoblast Limited

Mesoblast Licensee Files for Marketing Approval to Treat Epidermolysis Bullosa

NEW YORK and MELBOURNE, Australia, March 25, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced its licensee in Japan, JCR Pharmaceuticals Co. Ltd., has filed to...
March 22, 2019 16:36 ET | Source: Mesoblast Limited

U.S. Healthcare Leader Joseph R. Swedish Appointed Mesoblast Chairman

NEW YORK and MELBOURNE, Australia, March 22, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO; ASX: MSB) today announced it has appointed Joseph R. Swedish as non-executive Chairman. Mr...
March 13, 2019 06:00 ET | Source: Mesoblast Limited

Mesoblast Features at Upcoming U.S. Investor Conferences

NEW YORK and MELBOURNE, Australia, March 13, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced it will be featured at two investor conferences in March: ...
February 20, 2019 17:16 ET | Source: Mesoblast Limited

Mesoblast Reports Financial Results and Operational Highlights for the First Half Ended December 31, 2018

MELBOURNE, Australia and NEW YORK, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today reported its financial results and operational highlights for the six months ended...
February 19, 2019 06:00 ET | Source: Mesoblast Limited

Final Patient Dosed in Mesoblast Phase 3 Trial of Revascor Cell Therapy for Advanced Heart Failure

NEW YORK and MELBOURNE, Australia, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a world leader in development and commercialization of cellular medicines, announced...
February 13, 2019 17:06 ET | Source: Mesoblast Limited

Mesoblast Financial Results Webcast for Half Year, Q2 Ended December 31, 2018

NEW YORK and MELBOURNE, Australia, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) will report financial results for the half year and second quarter ended December 31,...
January 14, 2019 10:46 ET | Source: Mesoblast Limited

Hercules Capital Provides US$15M From Existing Facility for Mesoblast to Accelerate Product Commercialization Programs

NEW YORK and MELBOURNE, Australia, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced that it has drawn down a further US$15 million from its US$75 million,...
January 07, 2019 19:44 ET | Source: Mesoblast Limited

Mesoblast Highlights 2019 Key Priorities for its Leading Cellular Medicines Pipeline at Biotech Showcase in San Francisco

NEW YORK and MELBOURNE, Australia, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), world leader in the development and commercialization of cellular medicines, today...